PITTSBURGH, April 26 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq:MYL - News) today announced that its subsidiary Mylan Pharmaceuticals Inc. has begun to market Methamphetamine Hydrochloride Tablets USP, 5 mg, based on an agreement with licensing partner Coastal Pharmaceuticals. This product, used for the treatment of attention deficit hyperactivity disorder or obesity, is the first generic version of Lundbeck's Desoxyn® to be approved by the U.S. Food and Drug Administration (FDA).
